Industry

Brimonidine drop with sodium hyaluronate noninferior to Lumify

Healio Optometry2d ago1 min read

DENVER — Compared with original Lumify eye drops, a new formulation with sodium hyaluronate led to comparable reductions in eye redness, according to phase 3 data presented here.“We know the demands our patients have to treat redness. ... But along with that, so many of our patients are symptomatic because their eyes are constantly irritated — they have that dry feeling,” study author Shane R. Kannarr, OD, who practices at Kannarr Eye Care in Pittsburg, Kansas, told Healio. “Our patients are not only putting in a drop to reduce the redness but also putting in a drop to treat those early

Read full article on Healio Optometry

AI Summary

Quick Take

Phase 3 clinical data show that a new formulation of brimonidine eye drops containing sodium hyaluronate is noninferior to original Lumify for the reduction of ocular redness. This dual-action approach aims to provide the same whitening effect as the market leader while simultaneously addressing the irritation and dryness that often accompany red eyes.

Why It Matters

Patients frequently seek over-the-counter solutions for redness, but many are also symptomatic for ocular surface irritation and dryness. Currently, these patients often resort to using two separate products—a vasoconstrictor and a lubricant. A single-drop solution that combines the proven efficacy of low-dose brimonidine with the hydrating properties of sodium hyaluronate could simplify patient regimens and improve the overall comfort of the whitening experience.

Key Findings

The new formulation containing sodium hyaluronate achieved comparable reductions in eye redness to the original Lumify formulation.
Phase 3 data supports the noninferiority of the combination drop for its primary efficacy endpoint.
The formulation is specifically designed to address the 'dry feeling' and irritation frequently reported by patients seeking redness relief.

Study Snapshot

Design

Phase 3 clinical trial

Population

Patients with eye redness and concurrent ocular irritation

Practice Implications

Clinicians should monitor for the release of this formulation as a potential first-line OTC recommendation for patients who desire eye whitening but also suffer from mild ocular surface discomfort. This could eliminate the need for patients to juggle separate lubricating and whitening drops, potentially increasing satisfaction with the cosmetic outcome.

Who's Affected

OptometristsOphthalmologistsDry Eye SpecialistsContact Lens Fitters

What's Next

Following the presentation of this Phase 3 data, the industry will look toward regulatory milestones and a potential commercial launch date for this combination formulation.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.